Reteplase contraindications
| Reteplase |
|---|
| Retavase® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Reteplase |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
Because thrombolytic therapy increases the risk of bleeding, Retavase® is contraindicated in the following situations
*Active internal bleeding
*History of cerebrovascular accident
*Recent intracranial or intraspinal surgery or trauma (see WARNINGS)
*Intracranial neoplasm, arteriovenous malformation, or aneurysm
*Known bleeding diathesis
*Severe uncontrolled hypertension[1]:
References
Adapted from the FDA Package Insert.